BioTuesdays

Category - Markets

PepGen

SVB Securities starts PepGen at OP; PT $40

SVB Securities launched coverage of PepGen (NASDAQ:PEPG) with an “outperform” rating and $40 price target. The stock closed at $10.88 on May 27. PepGen is a clinical-stage biotech advancing its enhanced delivery...

Liquidia Logo

BTIG starts Liquidia at buy; PT $14 

BTIG initiated coverage of Liquidia (NASDAQ:LQDA) with a “buy” rating and $14 price target. The stock closed at $4.07 on May 27. Analyst Julian Harrison writes that Liquidia has brought its lead candidate, YUTREPIA, to...

SVB cuts Avadel Pharma PT to $6 from $18

SVB Securities slashed the price target of Avadel Pharmaceuticals (NASDAQ:AVDL) to $6 from $18, but maintained an “overweight” rating, after the FDA delayed full approval of FT-218 because of a patent issue.  Shares of...

Maxim reduces PTs in challenging biotech market

Maxim Group analyst Jason McCarthy, Ph.D., reduced price targets for 13 stocks in his coverage universe, citing macroeconomic winds and a significant decline in stock prices, particularly for small-cap biotech stocks...

Pliant Therapeutics

Cantor starts Pliant Therapeutics at OW; PT $12

Cantor Fitzgerald launched coverage of Pliant Therapeutics (NASDAQ:PLRX) with an “overweight” rating and 12-month price target of $12. The stock closed at $4.93 on May 24. Pliant is developing novel therapies for...

Cantor starts Lyra Therapeutics at OW; PT $15

Cantor Fitzgerald initiated coverage of Lyra Therapeutics (NASDAQ:LYRA) with an “overweight” rating and price target of $15. The stock closed at $6.07 on May 23. Lyra is a clinical-stage company developing medicines...

HilleVax

Analysts start HilleVax at buy, outperform

Analysts for Stifel and SVB Securities initiated coverage of HilleVax (NASDAQ:HLVX) with “buy” and “outperform” ratings, and price targets of $34 and $30, respectively. The stock closed at $9.50 on May 23. The company’s...

Humacyte

Piper cuts Humacyte to underweight; PT to $4 from $10

Piper Sandler downgraded Humacyte (NASDAQ:HUMA) to “underweight” from “overweight” and reduced its price target to $4 from $10, citing the sizable stock pullback in the sector. The stock closed at $5.37 on May 13. The...

89bio

BTIG slashes 89bio PT to $28 from $60

BTIG reduced its price target for 89bio (NASDAQ:ETNB) to $28 from $60 but maintained its “buy” rating after making model updates and increasing its modeled discount rate to 14% from 12%. The stock closed at $2.67 on May...

Pulse Biosciences Logo

HCW cuts Pulse Biosciences to neutral; withdraws PT

H.C. Wainwright downgraded Pulse Biosciences (NASDAQ:PLSE) to “neutral” from “buy” without a price target, reflecting a lack of clarity about Pulse’s commercial timelines and funding availability. The stock closed at $1...